A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Empasiprubart (Primary) ; Immune globulin
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Acronyms EMVIGORATE
- Sponsors argenx
Most Recent Events
- 23 Sep 2025 Planned End Date changed from 1 May 2030 to 1 Sep 2030.
- 23 Sep 2025 Planned primary completion date changed from 1 May 2027 to 1 Sep 2027.
- 23 Sep 2025 Planned initiation date changed from 1 May 2025 to 22 Aug 2025.